Sonia Gregory | Scientific Leader
GSK Vaccines

Sonia Gregory, Scientific Leader, GSK Vaccines

Dr. Sonia Gregory leads the Self Amplifying mRNA (SAM) CMC Platform team at GSK Vaccines, which is focused on process and product improvement, scale up, analytical strategy, QbD, rapid response, and acceleration of RNA products. She earned a BS and MS in Chemistry from the University of North Carolina Wilmington and a PhD in Biophysics from the University of Virginia. Sonia identified lead therapeutic molecules for progression into development using biophysical techniques at Merck and later transitioned into Technical Development at Novartis Vaccines now GSK Vaccines, where SAM originated. At GSK she has been a lead contributor on key programs where she optimized formulations, process development, and scale-up processes to enable meeting program milestones and clinical manufacture.


Day 2, April 8 @ 09:40

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

  • Why and where will it make a difference?
  • How is it difference to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like corona? Can the scale-up/volume be big enough?
  • Advantages of RNA are clearly from the speed and applicability to ID and cancer, but does the speed have any affect on the overall quality of the vaccine?
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates